Cell Discovery (Aug 2023)

TET2 is required to suppress mTORC1 signaling through urea cycle with therapeutic potential

  • Jing He,
  • Mingen Lin,
  • Xinchao Zhang,
  • Ruonan Zhang,
  • Tongguan Tian,
  • Yuefan Zhou,
  • Wenjing Dong,
  • Yajing Yang,
  • Xue Sun,
  • Yue Dai,
  • Yue Xu,
  • Zhenru Zhang,
  • Ming Xu,
  • Qun-Ying Lei,
  • Yanping Xu,
  • Lei Lv

DOI
https://doi.org/10.1038/s41421-023-00567-7
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Tumor development, involving both cell growth (mass accumulation) and cell proliferation, is a complex process governed by the interplay of multiple signaling pathways. TET2 mainly functions as a DNA dioxygenase, which modulates gene expression and biological functions via oxidation of 5mC in DNA, yet whether it plays a role in regulating cell growth remains unknown. Here we show that TET2 suppresses mTORC1 signaling, a major growth controller, to inhibit cell growth and promote autophagy. Mechanistically, TET2 functions as a 5mC “eraser” by mRNA oxidation, abolishes YBX1–HuR binding and promotes decay of urea cycle enzyme mRNAs, thus negatively regulating urea cycle and arginine production, which suppresses mTORC1 signaling. Therefore, TET2-deficient tumor cells are more sensitive to mTORC1 inhibition. Our results uncover a novel function for TET2 in suppressing mTORC1 signaling and inhibiting cell growth, linking TET2-mediated mRNA oxidation to cell metabolism and cell growth control. These findings demonstrate the potential of mTORC1 inhibition as a possible treatment for TET2-deficient tumors.